JP2022527190A5 - - Google Patents
Info
- Publication number
- JP2022527190A5 JP2022527190A5 JP2021557925A JP2021557925A JP2022527190A5 JP 2022527190 A5 JP2022527190 A5 JP 2022527190A5 JP 2021557925 A JP2021557925 A JP 2021557925A JP 2021557925 A JP2021557925 A JP 2021557925A JP 2022527190 A5 JP2022527190 A5 JP 2022527190A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- hexenoyl
- ghrh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826284P | 2019-03-29 | 2019-03-29 | |
| US62/826,284 | 2019-03-29 | ||
| US201962861187P | 2019-06-13 | 2019-06-13 | |
| US62/861,187 | 2019-06-13 | ||
| PCT/US2020/025180 WO2020205498A1 (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527190A JP2022527190A (ja) | 2022-05-31 |
| JP2022527190A5 true JP2022527190A5 (cg-RX-API-DMAC10.html) | 2023-04-05 |
Family
ID=72607731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557925A Pending JP2022527190A (ja) | 2019-03-29 | 2020-03-27 | 肝疾患の治療で使用するためのｇｈｒｈまたはその類似物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10799562B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3947426A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022527190A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210145226A (cg-RX-API-DMAC10.html) |
| CN (1) | CN113646327A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020253828A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3133319A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL286703A (cg-RX-API-DMAC10.html) |
| SG (1) | SG11202110469PA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020205498A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020205498A1 (en) * | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CA3183299A1 (en) * | 2020-07-05 | 2022-01-13 | Christian Marsolais | Low-dose pharmaceutical compositions of ghrh analogs and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010675A (es) * | 2007-04-04 | 2009-10-23 | Theratechnologies Inc | Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana. |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20150174207A1 (en) * | 2013-12-24 | 2015-06-25 | University Of Miami | Methods for treating cancer with ghrh agonists |
| EP3362053A4 (en) * | 2015-10-16 | 2019-04-17 | Hadasit Medical Research Services and Development Ltd. | TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE |
| MX2018012716A (es) * | 2016-04-19 | 2019-02-11 | Griffon Pharmaceuticals Inc | Peptidos bioactivos pegilados y usos de los mismos. |
| EP4467158A3 (en) * | 2018-02-14 | 2025-02-19 | Lumos Pharma, Inc. | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| WO2020205498A1 (en) * | 2019-03-29 | 2020-10-08 | The General Hospital Corporation | Ghrh or analogues thereof for use in treatment of hepatic disease |
| JP2023548156A (ja) * | 2020-10-30 | 2023-11-15 | ザ ジェネラル ホスピタル コーポレイション | 肝疾患の評価のためのキット、試薬、及び方法 |
| WO2022104289A1 (en) * | 2020-11-16 | 2022-05-19 | The Regents Of The University Of California | Use of pharmaceutical doses of niacin, or an analog thereof, for the regression or reversal of fibrosis and/or liver cirrhosis |
-
2020
- 2020-03-27 WO PCT/US2020/025180 patent/WO2020205498A1/en not_active Ceased
- 2020-03-27 AU AU2020253828A patent/AU2020253828A1/en not_active Abandoned
- 2020-03-27 US US16/832,128 patent/US10799562B1/en active Active
- 2020-03-27 EP EP20784029.9A patent/EP3947426A4/en not_active Withdrawn
- 2020-03-27 KR KR1020217034940A patent/KR20210145226A/ko not_active Ceased
- 2020-03-27 CN CN202080025127.2A patent/CN113646327A/zh active Pending
- 2020-03-27 SG SG11202110469PA patent/SG11202110469PA/en unknown
- 2020-03-27 JP JP2021557925A patent/JP2022527190A/ja active Pending
- 2020-03-27 CA CA3133319A patent/CA3133319A1/en active Pending
- 2020-09-11 US US17/018,878 patent/US10946073B2/en active Active
-
2021
- 2021-02-08 US US17/170,579 patent/US11738066B2/en active Active
- 2021-09-26 IL IL286703A patent/IL286703A/en unknown
-
2023
- 2023-07-12 US US18/351,169 patent/US12233107B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6250588B2 (ja) | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
| Sahud et al. | Effect of aspirin ingestion on ascorbic-acid levels in rheumatoid arthritis | |
| Falasca et al. | Treatment with silybin‐vitamin E‐phospholipid complex in patients with hepatitis C infection | |
| US20210322407A1 (en) | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | |
| CA2440744C (en) | Il-12 expression controlling agent | |
| CA3049703A1 (en) | New use of a long-acting mutant human fibroblast growth factor | |
| CN109381472A (zh) | 一种糖苷类化合物在制备用于治疗肝纤维化药物中的应用 | |
| JP2008542380A (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| KR20150130352A (ko) | 지방간 질환을 치료하는 방법 | |
| CN119424436B (zh) | 化合物rociletinib通过抑制铁死亡在制备急性肝损伤的药物中的应用 | |
| Turdiyev et al. | CHOLERETIC ACTIVITY OF RUTANA AT THERAPEUTIC APPLICATION IN RATS WITH HELIOTRIN HEPATITIS | |
| CN113069445A (zh) | 牛防风素作为有效成分在制备乙型肝炎治疗药物中的用途 | |
| US11278542B2 (en) | Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib | |
| AU2018446089B2 (en) | Pharmaceutical use of anemoside B4 against acute gouty arthritis | |
| CN114366732B (zh) | 泰妙菌素在制备用于治疗银屑病的药物中的应用 | |
| WO2024230460A1 (zh) | 五环三萜结构修饰化合物在制备白癜风药物中的应用及新制剂 | |
| CN112294787B (zh) | 一种治疗肝癌的联合用药物 | |
| Ashraf et al. | An open-label randomized clinical study to compare the effects of a nutritional supplement versus vitamin E on fibroscan score in nonalcoholic steatohepatitis (NASH) patients | |
| CN113244208A (zh) | Hpa在制备治疗非酒精性脂肪性肝病药物中的应用 | |
| CN111904967A (zh) | 2-apb在制备治疗非酒精性脂肪性肝炎的药物中的应用 | |
| AU2009274022B2 (en) | Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis | |
| RU2785582C2 (ru) | Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита | |
| CN121243146A (zh) | 3,5-二甲氧基-4-(2-氨基-3-(2-炔-丙硫烷)-丙酰基)-苯甲酸4-胍基-丁酰酯在医学中的新应用 | |
| CN117982489A (zh) | 蟛蜞菊内酯防治非酒精性脂肪性肝病的应用 |